Nonproportional Hazards—An Evaluation of the MaxCombo Test in Cancer Clinical Trials

References

• Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., Banos, A., Tiab, M., Delforge, M., Cavenagh, J., Geraldes, C., Lee, J.-J., Chen, C., Oriol, A., de la Rubia, J., Qiu, L., White, D. J., Binder, D., Anderson, K., Fermand, J.-P., Moreau, P., Attal, M., Knight, R., Chen, G., Van Oostendorp, J., Jacques, C., Ervin-Haynes, A., Avet-Loiseau, H., Hulin, C., and Facon, T. (2014), “Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma,” New England Journal of Medicine, 371, 906–917. DOI: 10.1056/NEJMoa1402551.
   PubMed Web of Science ®Google Scholar
• Bevacizumab-ProductLabel (2020), “Genentech,” available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125085s337lbl.pdf
   Google Scholar
• Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., Boente, M., Birrer, M. J., and Liang, S. X. (2011), “Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer,” New England Journal of Medicine, 365, 2473–2483. DOI: 10.1056/NEJMoa1104390.
   PubMed Web of Science ®Google Scholar
• Duke-Margolis Workshop (2018), “Public Workshop: Oncology Clinical Trials in the Presence of Non-Proportional Hazards,” available at https://healthpolicy.duke.edu/events/public-workshop-oncology-clinical-trials-presence-non-proportional-hazards
   Google Scholar
• Fine, G. D. (2007), “Consequences of Delayed Treatment Effects on Analysis of Time-to-Event Endpoints,” Drug Information Journal, 41, 535–539. DOI: 10.1177/009286150704100412.
   Web of Science ®Google Scholar
• Freidlin, B., and Korn, E. L. (2019), “Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 37, 3455–3459. DOI: 10.1200/JCO.19.01681.
   PubMed Web of Science ®Google Scholar
• Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., Melichar, B., Tehfe, M., Topuzov, E., Zalcberg, J. R., Chau, I., Campbell, W., Sivanandan, C., Pikiel, J., Koshiji, M., Hsu, Y., Liepa, A. M., Gao, L., Schwartz, J. D., and Tabernero, J. (2014), “Ramucirumab Monotherapy for Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma (REGARD): An International, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial,” The Lancet, 383, 31–39. DOI: 10.1016/S0140-6736(13)61719-5.
   PubMed Web of Science ®Google Scholar
• Grambsch, P. M., and Therneau, T. M. (1994), “Proportional Hazards Tests and Diagnostics Based on Weighted Residuals,” Biometrika, 81, 515–526. DOI: 10.1093/biomet/81.3.515.
   Web of Science ®Google Scholar
• Harrington, D. P., and Fleming, T. R. (1982), “A Class of Rank Test Procedures for Censored Survival Data,” Biometrika, 69, 553–566. DOI: 10.1093/biomet/69.3.553.
   Web of Science ®Google Scholar
• Hodi, F. S., O’Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J. M., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A., and Urba, W. J. (2010), “Improved Survival with Ipilimumab in Patients with Metastatic Melanoma,” New England Journal of Medicine, 363, 711–723. DOI: 10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• ICH E9 (R1) (2019), “Addendum on Estimands and Sensitivity Analysis in Clinical Trials – To the Guideline on Statistical Principles for Clinical Trials,” available at https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf
   Google Scholar
• Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O’Brien, S., Wang, K., Wang, T., Paccagnella, M. L., Sleight, B., Vandendries, E., and Advani, A. S. (2016), “Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia,” New England Journal of Medicine, 375, 740–753. DOI: 10.1056/NEJMoa1509277.
   PubMed Web of Science ®Google Scholar
• Karrison, T. G. (2016), “Versatile Tests for Comparing Survival Curves Based on Weighted Log-rank Statistics,” The Stata Journal: Promoting Communications on Statistics and Stata, 16, 678–690. DOI: 10.1177/1536867X1601600308.
   Google Scholar
• Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., Leon, L. F., Liao, J. J. Z., Liu, R., Luo, X., Mukhopadhyay, P., Qin, R., Tatsuoka, K., Wang, X., Wang, Y., Zhu, J., Chen, T.-T., and Iacona, R, Cross-Pharma Non-Proportional Hazards Working Group. (2020a), “Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis,” Statistics in Biopharmaceutical Research, 12, 187–198. DOI: 10.1080/19466315.2019.1697738.
   Web of Science ®Google Scholar
• Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., Leon, L. F., Liao, J. J. Z., Liu, R., Luo, X., Mukhopadhyay, P., Qin, R., Tatsuoka, K., Wang, X., Wang, Y., Zhu, J., Chen, T.-T., and Iacona, R, Cross-Pharma Non-Proportional Hazards Working Group. (2020b), Rejoinder to Letter to the Editor “The Hazards of Period Specific and Weighted Hazard Ratios,” Statistics in Biopharmaceutical Research, 12, 520–521.
   PubMed Web of Science ®Google Scholar
• Magirr, D., and Burman, C.-F. (2021), “The Strong Null Hypothesis and the MaxCombo Test: Comment on “Robust Design and Analysis of Clinical Trials with Nonproportional Hazards: A Straw Man Guidance form a Cross-Pharma Working Group,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2021.1917451.
   Web of Science ®Google Scholar
• Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.-J., Chewaskulyong, B., Jiang, H., Duffield, E. L., Watkins, C. L., Armour, A. A., and Fukuoka, M. (2009), “Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma,” New England Journal of Medicine, 361, 947–957. DOI: 10.1056/NEJMoa0810699.
   PubMed Web of Science ®Google Scholar
• Mok, T. S. K., Wu, Y.-L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., Kubota, K., Lubiniecki, G. M., Zhang, J., Kush, D., Lopes, G., Adamchuk, G., Ahn, M.-J., Alexandru, A., Altundag, O., Alyasova, A., Andrusenko, O., Aoe, K., Araujo, A., Aren, O., Arrieta Rodriguez, O., Ativitavas, T., Avendano, O., Barata, F., Barrios, C. H., Beato, C., Bergstrom, P., Betticher, D., Bolotina, L., Bondarenko, I., Botha, M., Buddu, S., Caglevic, C., Cardona, A., Castro, G., Castro, H., Cay Senler, F., Cerny, C. A. S., Cesas, A., Chan, G.-C., Chang, J., Chen, G., Chen, X., Cheng, S., Cheng, Y., Cherciu, N., Chiu, C.-H., Cho, B. C., Cicenas, S., Ciurescu, D., Cohen, G., Costa, M. A., Danchaivijitr, P., De Angelis, F., de Azevedo, S. J., Dediu, M., Deliverski, T., De Marchi, P. R. M., de The Bustamante Valles, F., Ding, Z., Doganov, B., Dreosti, L., Duarte, R., Edusma-Dy, R., Emelyanov, S., Erman, M., Fan, Y., Fein, L., Feng, J., Fenton, D., Fernandes, G., Ferreira, C., Franke, F. A., Freitas, H., Fujisaka, Y., Galindo, H., Galvez, C., Ganea, D., Gil, N., Girotto, G., Goker, E., Goksel, T., Gomez Aubin, G., Gomez Wolff, L., Griph, H., Gumus, M., Hall, J., Hart, G., Havel, L., He, J., He, Y., Hernandez Hernandez, C., Hespanhol, V., Hirashima, T., Ho, C. M. J., Horiike, A., Hosomi, Y., Hotta, K., Hou, M., How, S. H., Hsia, T.-C., Hu, Y., Ichiki, M., Imamura, F., Ivashchuk, O., Iwamoto, Y., Jaal, J., Jassem, J., Jordaan, C., Juergens, R. A., Kaen, D., Kalinka-Warzocha, E., Karaseva, N., Karaszewska, B., Kazarnowicz, A., Kasahara, K., Katakami, N., Kato, T., Kawaguchi, T., Kim, J. H., Kishi, K., Kolek, V., Koleva, M., Kolman, P., Koubkova, L., Kowalyszyn, R., Kowalski, D., Koynov, K., Ksienski, D., Kubota, K., Kudaba, I., Kurata, T., Kuusk, G., Kuzina, L., Laczo, I., Ladrera, G. E. I., Laktionov, K., Landers, G., Lazarev, S., Lerzo, G., Lesniewski Kmak, K., Li, W., Liam, C. K., Lifirenko, I., Lipatov, O., Liu, X., Liu, Z., Lo, S. H., Lopes, V., Lopez, K., Lu, S., Martinengo, G., Mas, L., Matrosova, M., Micheva, R., Milanova, Z., Miron, L., Mok, T., Molina, M., Murakami, S., Nakahara, Y., Nguyen, T. Q., Nishimura, T., Ochsenbein, A., Ohira, T., Ohman, R., Ong, C. K., Ostoros, G., Ouyang, X., Ovchinnikova, E., Ozyilkan, O., Petruzelka, L., Pham, X. D., Picon, P., Piko, B., Poltoratsky, A., Ponomarova, O., Popelkova, P., Purkalne, G., Qin, S., Ramlau, R., Rappaport, B., Rey, F., Richardet, E., Roubec, J., Ruff, P., Rusyn, A., Saka, H., Salas, J., Sandoval, M., Santos, L., Sawa, T., Seetalarom, K., Seker, M., Seki, N., Seolwane, F., Shepherd, L., Shevnya, S., Shimada, A. K., Shparyk, Y., Sinielnikov, I., Sirbu, D., Smaletz, O., Soares, J. P. H., Sookprasert, A., Speranza, G., Srimuninnimit, V., Sriuranpong, V., Stara, Z., Su, W.-C., Sugawara, S., Szpak, W., Takahashi, K., Takigawa, N., Tanaka, H., Tan Chun Bing, J., Tang, Q., Taranov, P., Tejada, H., Tho, L. M., Torii, Y., Trukhyn, D., Turdean, M., Turna, H., Ursol, G., Vanasek, J., Varela, M., Vallejo, M., Vera, L., Victorino, A.-P., Vlasek, T., Vynnychenko, I., Wang, B., Wang, J., Wang, K., Wu, Y., Yamada, K., Yang, C.-H., Yokoyama, T., Yokoyama, T., Yoshioka, H., Yumuk, F., Zambrano, A., Zarba, J. J., Zarubenkov, O., Zemaitis, M., Zhang, L., Zhang, L., Zhang, X., Zhao, J., Zhou, C., Zhou, J., Zhou, Q., and Zippelius, A. (2019), “Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial,” The Lancet, 393, 1819–1830. DOI: 10.1016/S0140-6736(18)32409-7.
   PubMed Web of Science ®Google Scholar
• Mulkey, F., By, K., Theoret, M. R., Maher, V. E., Pazdur, R., and Sridhara, R. (2019), “Analysis of Early Mortality in Randomized Clinical Trials Evaluating Anti-PD-1/PD-L1 Antibodies: A Systematic Analysis by the United States Food and Drug Administration (FDA),” Journal of Clinical Oncology, 37, 2516–2516. DOI: 10.1200/JCO.2019.37.15_suppl.2516.
   Web of Science ®Google Scholar
• Roychoudhury, S., Anderson, K. M., Ye, J., and Mukhopadhyay, P. (2021), “Robust Design and Analysis of Clinical Trials with Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2021.1874507.
   Web of Science ®Google Scholar
• Schemper, M., Wakounig, S., and Heinze, G. (2009), “The Estimation of Average Hazard Ratios by Weighted Cox Regression,” Statistics in Medicine, 28, 2473–2489. DOI: 10.1002/sim.3623.
   PubMed Web of Science ®Google Scholar
• Schoenfeld, D. (1982), “Partial Residuals for the Proportional Hazards Regression Model,” Biometrika, 69, 239–241. DOI: 10.1093/biomet/69.1.239.
   Web of Science ®Google Scholar
• Tsiatis, A. A. (1982), “Repeated Significance Testing for a General Class of Statistics Used in Censored Survival Analysis,” Journal of the American Statistical Association, 77, 855–861. DOI: 10.1080/01621459.1982.10477898.
   Web of Science ®Google Scholar
• Xu, R., and O’Quigley, J. (2000), “Estimating Average Regression Effect Under Non-Proportional Hazards,” Biostatistics (Oxford, England), 1, 423–439. DOI: 10.1093/biostatistics/1.4.423.
   PubMedGoogle Scholar